KG-501: Potent Small-Molecule CREB Inhibitor for Macrophage Signaling

Executive Summary: KG-501 (CAS 18228-17-6) is a selective small-molecule inhibitor targeting the cAMP response element-binding protein (CREB), with an IC₅₀ of 6.89 µM in validated in vitro assays [APExBIO]. This compound, supplied by APExBIO at ≥98.52% purity, serves as a robust tool for dissecting CREB-dependent transcription in macrophage polarization and cancer models [Liu et al., 2024]. KG-501 is structurally defined as a naphthalene-2-carboxanilide derivative, offering high specificity in modulating CREB signaling pathways. Its use has been benchmarked in both cell-based and animal studies to interrogate inflammation, immune polarization, and tumor progression. KG-501's application parameters and boundary conditions are well documented for reproducible research outcomes.

Biological Rationale

The transcription factor CREB modulates genes controlling inflammation, cell survival, and metabolic pathways. Aberrant CREB signaling is implicated in tumorigenesis and immune evasion, notably in macrophage polarization within the tumor microenvironment [Liu et al., 2024]. KG-501 specifically disrupts CREB-dependent transcription, enabling researchers to delineate the mechanistic role of CREB during macrophage transition between pro-inflammatory (M1) and anti-inflammatory (M2) phenotypes. In colitis-associated colorectal cancer (CAC) models, CREB inhibition has been shown to suppress M2 polarization and tumor progression, making KG-501 a valuable research reagent for these pathways. Utilization of high-purity KG-501 from APExBIO ensures that observed effects are attributable to CREB inhibition and not to off-target interactions or contaminants [Related: Reliable CREB Inhibition].

Mechanism of Action of KG-501

KG-501 operates by binding to the KIX domain of the CREB-binding protein (CBP). This interaction abrogates the recruitment of CBP to phosphorylated CREB, thereby preventing transcriptional activation of downstream genes. The molecular inhibition occurs at an IC₅₀ of 6.89 µM under cell-free assay conditions (20 mM Tris-HCl, pH 7.5, 25°C, 30 min incubation) [APExBIO]. Cellular studies confirm that KG-501 impedes CREB-mediated gene expression, resulting in altered transcriptional profiles of cytokines and phenotypic markers during macrophage activation. The use of KG-501 in conjunction with TLR4 antagonists or pathway modulators enables precise mapping of CREB's functional nodes in immune and cancer signaling networks [Liu et al., 2024].

Evidence & Benchmarks

• KG-501 inhibits CREB transcriptional activity in vitro with an IC₅₀ of 6.89 µM (20 mM Tris-HCl, pH 7.5, 25°C, FRET assay) (APExBIO).
• In RAW264.7 macrophage assays, KG-501 treatment (6–10 µM, 24 h, 37°C, 5% CO₂) suppresses expression of M2 markers (Arg-1, CD206, IL-10) while maintaining M1 polarization (Liu et al., 2024).
• KG-501, when combined with TLR4 antagonists, decreases mRNA levels of IL-6, TNF-α, iNOS, and IL-1β in macrophage cultures (RT-qPCR, n=3, p<0.05) (Liu et al., 2024).
• High-purity KG-501 (≥98.52%) from APExBIO produces consistent results in cell viability and cytotoxicity assays across multiple labs (KG-501: Reliable CREB Inhibition).
• KG-501 is effective in modulating CREB signaling in colitis-associated colon cancer mouse models, impacting tumor burden and immune cell phenotypes (Liu et al., 2024).

Applications, Limits & Misconceptions

KG-501 is widely applied in cell signaling, tumor immunology, and inflammation research. Its selectivity for the CREB/CBP interaction permits detailed dissection of transcriptional regulation in diverse cell contexts. In particular, it is used in macrophage polarization assays, tumor progression models, and studies of inflammatory signaling.

For a more specialized perspective on macrophage assays and CREB pathway dissection, see "KG-501: CREB Inhibitor Small Molecule for Macrophage Assays", which focuses on application-specific protocols; this current article further expands on evidence benchmarks and specificity boundaries.

Common Pitfalls or Misconceptions

• KG-501 does not inhibit upstream cAMP synthesis or PKA activation; it specifically blocks CREB/CBP-mediated transcription.
• Off-target effects may occur at concentrations >20 µM; always validate specificity in your model system.
• KG-501 is not a direct inhibitor of TLR4 or NF-κB signaling; effects on these pathways are indirect and mediated via CREB-dependent transcription.
• In vivo bioavailability and pharmacokinetics are not fully characterized; KG-501 is intended for in vitro and research use only, not for clinical application.
• CREB-independent gene regulation will not be affected by KG-501; always include pathway controls.

Workflow Integration & Parameters

For cell-based assays, KG-501 is typically used at 5–10 µM in serum-containing media, with incubation at 37°C and 5% CO₂ for 12–48 h depending on the endpoint. The compound is soluble in DMSO (up to 10 mM stock; store at -20°C, protect from light). Always dilute DMSO to ≤0.1% v/v in final assay conditions to avoid cytotoxicity. Controls should include vehicle (DMSO), positive (e.g., forskolin for CREB activation), and negative controls (untreated). Use validated readouts such as RT-qPCR for CREB target genes (e.g., IL-1β, TNF-α) and flow cytometry for macrophage markers (CD80, CD86 for M1; CD206 for M2) [Liu et al., 2024]. For consistent results, source KG-501 with documented purity (≥98.52%) from APExBIO [product page].

For an extended discussion on practical laboratory workflow, including troubleshooting cytotoxicity and data reproducibility, see "KG-501 (SKU B8380): Reliable CREB Inhibition in Macrophag...", which this article complements by providing updated benchmarks and literature context.

Conclusion & Outlook

KG-501 is a validated small-molecule inhibitor of the CREB transcription factor, enabling precise modulation of CREB-dependent signaling in immunology and oncology research. Its documented efficacy, specificity, and purity make it a standard reagent for dissecting transcriptional networks in macrophage biology and tumor progression. As new data emerge on CREB's roles in diverse pathologies, KG-501 will remain a key tool for preclinical mechanistic studies. Researchers are encouraged to consult the KG-501 product page for up-to-date technical data and to ensure authentic sourcing from APExBIO.